Mineralys Therapeutics (MLYS) Return on Equity (2022 - 2026)

Mineralys Therapeutics has disclosed Return on Equity across 5 years of filings, most recently posting 0.0% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
• Return on Equity came in at 0.0% for Q1 2026 at Mineralys Therapeutics, up from 0.0% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.01% in Q4 2022 to a low of 0.01% in Q4 2024.
• The 5-year median for Return on Equity is 0.0% (2024), against an average of 0.0%.
• Across the five-year window, Return on Equity fell 1 bps in 2023 and grew 1 bps in 2025, its largest moves.
• Mineralys Therapeutics' Return on Equity stood at 0.01% in 2022, then slumped by 146 bps to 0.0% in 2023, then sank by 192 bps to 0.01% in 2024, then soared by 70 bps to 0.0% in 2025, then gained by 7 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.